NASDAQ$ROIV
Roivant Sciences Ltd · Q4 2025 earnings
Q4 2025 earnings · · Before market open · Investor relations
Briefing
Roivant Sciences reported a net loss in Q4 2025, with lower revenue and increased R&D and G&A expenses.
Roivant Sciences ended Q4 2025 with a net loss of $206.5 million as operating expenses surged due to higher R&D and G&A costs. Revenue dipped slightly from the prior year. Adjusted EPS came in below zero, reflecting ongoing investment in its late-stage pipeline.
- Revenue for Q4 2025 was $7.57 million, down from $9.02 million in Q4 2024.
- Net loss was $206.5 million, primarily due to increased operating expenses.
- Adjusted EPS was $(0.22), reflecting non-cash share-based compensation.
- Roivant maintained a strong cash position with $4.9 billion in total liquidity.
Headline financials
Revenue & EPS history
Roivant Sciences · Revenue · Quarterly
$7.57M
Forward guidance
Roivant anticipates key data readouts and trial initiations in late 2025 and 2026, driven by brepocitinib and IMVT-1402 programs.
Tailwinds
- Brepocitinib Phase 3 DM topline data expected in H2 2025
- CS proof-of-concept trial topline readout expected in H2 2026
- IMVT-1402 trials in GD and SjD to begin in summer 2025
- Strong cash runway of $4.9B supports long-term plans
- Multiple registrational programs progressing on schedule
Headwinds
- Continued net losses due to high operating costs
- Revenue decline versus prior year quarter
- Loss from continuing operations widened significantly
- Substantial share-based compensation burden
- High burn rate from expanded clinical activities
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2025
+3.3%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+0.4%
Avg return
30 days after
60%
12 / 20 earnings
Positive
+22.1%
Q3 2026
Best reaction
-5.5%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +14.9% | — | — | |
| Q3 2026 | +22.1% | +26.8% | +36.1% | |
| Q2 2026 | +2.6% | -1.6% | -1.8% | |
| Q1 2026 | -2.8% | +3.1% | +19.8% | |
| Q4 2025 | +6.4% | +5.9% | +7.3% | |
| Q4 2024 | -3.4% | +0.0% | -1.5% | |
| Q3 2024 | +4.1% | +6.6% | -5.9% | |
| Q2 2024 | +5.6% | +1.8% | +22.7% | |
| Q1 2024 | -5.2% | -6.1% | -3.5% | |
| Q4 2023 | +9.4% | +7.8% | +28.8% | |
| Q3 2023 | +9.7% | +8.2% | +7.8% | |
| Q2 2023 | +7.4% | -3.1% | +39.9% | |
| Q1 2023 | -5.5% | -15.3% | -15.8% | |
| Q4 2022 | -4.1% | -5.6% | -11.8% | |
| Q3 2021 | +5.1% | -3.2% | -25.4% | |
| Q3 2022 | +5.4% | -3.2% | -25.4% | |
| Q2 2022 | -2.4% | -4.8% | +6.8% | |
| Q2 2021 | -3.8% | -4.8% | +6.8% | |
| Q1 2021 | +0.1% | +0.7% | -38.7% | |
| Q1 2022 | +0.0% | +0.7% | -38.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro